近日，美国威斯康星大学麦迪逊分校研究学者在期刊《Journal for ImmunoTherapy of Cancer》上发表了研究论文，题为“Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial Of 118 ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The androgen receptor is a key transcriptional factor for the proper sex development -- especially in males -- and the physiological balance of all the tissues that express this receptor. The androgen ...

"Anti-androgen therapy can fuel spread of bone tumors in advanced prostate cancer." ScienceDaily. www.sciencedaily.com / releases / 2021 / 07 / 210707112445.htm (accessed February 13, 2026).